Business Wire

CIRIUM

1.12.2022 09:02:37 CET | Business Wire | Press release

Share
New Cirium Airline Finance Rankings Show an Industry Net Loss of Nearly $220 Billion Since the Pandemic Began

Cirium’s analysis of the World Airline Group Finance Rankings results for 2021 and the first half of 2022, shows how the steep decline in airline revenues has translated into a net loss of nearly $220 billion over the past two and a half years since the pandemic began.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005382/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cirium airline group corporate financial results for the first half of 2022. (Photo: Business Wire)

The full extent of damage from the pandemic shows through in the latest Cirium airline rankings. Revenues for the world’s airline groups more than halved in 2020 and, despite some recovery, ended 2021 still down by over 40% on pre-pandemic levels. At $500 billion, revenues remain lower than they were 15 years ago.

With most airline financial results in for the first half of 2022, there are further signs of recovery from the depth of the crisis, but the industry is expected to show another loss for the whole of 2022.

Jeremy Bowen, CEO at Cirium said: “It’s a positive sign that the net deficit is decreasing year-over-year. In 2020, the revenue decline translated into net losses of $160 billion, another $42 billion last year and losses for the first half of this year total around $15 billion.

“If losses so far this year aren’t substantially added to, that would leave the airline industry with the overall net loss of nearly $220 billion since the start of 2020. However, if we assume that there are no further shocks to the industry, there is the possibility that the industry may break even in the second half of the year, led by US and European groups.”

Demand has been recovering, with global revenues up by 70% for the first six months of 2022, bringing the total to within 20% of 2019 levels.

Cirium’s World Airline Group Finance Rankings for the first half of 2022 shows strongest progress from the North American carriers as they marked up a 5% increase over pre-pandemic levels and returned to a modest operating profit.

Delta Air Lines returns to the top of the revenue ranking this year, with revenue virtually back to pre-pandemic levels. The Federal Express (FedEx) air cargo operation narrowly slips to second spot, having led throughout the pandemic thanks to a strong global air freight market, driven by surging demand for PPE and ecommerce.

Early results for the September quarter show the six largest US carriers now with record revenues and an overall net profit for the first nine months of the year, putting the industry on course to post a modest profit for the year if trends continue.

The major European airline groups such as Lufthansa, also showed strong recovery in first half revenues, following the lifting of travel restrictions in early 2022 which unleashed a wave of passenger demand.

Traffic within Western Europe has been running at around 95% of pre-pandemic levels since the middle of the year, raising revenues and returning the largest groups to profitability in the September quarter.

By contrast, the Asia-Pacific region has struggled, largely because of China’s continued COVID-19 lockdowns. Chinese airlines posted a 35% decline in revenue and a net loss of nearly $10 billion in the first half of 2022, higher than either of the previous two years. The results going into the second half of the year look likely to add to that deficit. That is likely to be offset to an extent by airlines within the rest of the region, but on current performance that looks unlikely to be enough to counter the deficit flowing from China.

Rank

 

Airline Group

 

Country

 

Revenue ($m)

 

Change (%)

 

Op Result

 

Operating Margin (%)

 

Net Result

 

Net Margin (%)

2022

 

2019

     

2022

 

22 v 21

 

22 v 19

 

2022

 

2022

 

2021

 

2020

 

2019

 

2022

 

2022

 

2021

 

2020

 

2019

1

 

1

 

Delta Air Lines

 

USA

 

23,172

 

105

%

 

1

%

 

736

 

3

%

 

-5

%

 

-52

%

 

14

%

 

-205

 

-1

%

 

-5

%

 

-62

%

 

9

%

2

 

5

 

FedEx

 

USA

 

23,072

 

8

%

 

23

%

 

1,599

 

7

%

 

7

%

 

2

%

 

6

%

 

1,402

 

6

%

 

7

%

 

3

%

 

6

%

3

 

2

 

American Airlines

 

USA

 

22,321

 

94

%

 

-1

%

 

-706

 

-3

%

 

-8

%

 

-50

%

 

7

%

 

-1,159

 

-5

%

 

-11

%

 

-42

%

 

4

%

4

 

3

 

United Airlines

 

USA

 

19,678

 

126

%

 

-6

%

 

-498

 

-3

%

 

-19

%

 

-28

%

 

9

%

 

-1,048

 

-5

%

 

-21

%

 

-35

%

 

6

%

5

 

4

 

Lufthansa

 

Germany

 

16,107

 

108

%

 

-23

%

 

-215

 

-1

%

 

-29

%

 

-31

%

 

2

%

 

-353

 

-2

%

 

-28

%

 

-39

%

 

-1

%

If the industry does manage to contain its net loss for the full year around the $10-15 billion mark, it is worth remembering that is still equivalent to industry annual losses 20 years before in the wake of the crisis that followed the 9/11 attacks.

Cirium’s World Airline Group Passenger Rankings for 2021 and First Half of 2022 is a premium analysis available in Cirium Dashboard. The report features:

  • Top 25 airline groups by revenue ($m) Jan-Jun 2022
  • Top 100 airline groups by revenue ($m) 2021
  • Airline group corporate financial results by region Jan-Jun 2022 ($bn)
  • Passenger volumes by region Jan-Jun 2022
  • Airline group corporate financial results by region and airline type 2019-2021 ($bn)

Click here to download the full report.

Ends

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005382/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye